Tag:

Merck

Latest Headlines

Latest Headlines

Merck ramps up Belsomra marketing, hoping to wake up a sleepy insomnia market

Can a new kind of sleep aid rejuvenate the sleepy insomnia market? Merck is hoping so, pushing its new wakefulness-blocker drug Belsomra with an expanded marketing campaign.

One dose of GlaxoSmithKline's Cervarix may suffice

The recommended schedule for HPV vaccination is two or three doses, but some patients never make it back for all of the shots. This may cease to be a concern if future trials prove what scientists reported on Wednesday: A single dose of GlaxoSmithKline's Cervarix could work as well as the recommended two- or three-dose regimens at preventing the majority of cervical cancers.

UPDATED: Blockbuster-to-be cancer meds outclass other big launches--except Sovaldi and statins

No question, immuno-oncology drugs are the hottest tickets in cancer--and among the hottest across the board. But PD-1/PD-L1 treatments, including Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo, aren't the first to bear big sales expectations. How do immuno-oncology forecasts stack up against other notable drug launches?

Whistleblowers accuse Merck of withholding info on mumps vaccine

If Merck has answers regarding the efficacy of its mumps vaccine, it's not being forthright, says a letter filed by an attorney representing two former Merck virologists who are now whistleblowers.

Massachusetts General Hospital pits BCG vaccine against Type I diabetes in Ph II

Another indication may be on the horizon for the generic BCG vaccine as Massachusetts General Hospital got an OK from the FDA for a Phase II trial of the vaccine's ability to help patients with Type I diabetes.

Samsung Bioepis, Celltrion propel South Korea to front ranks of biosimilar race

South Korea's Celltrion and Samsung Bioepis are poised to gain new or expanded approval for biosimilars of some of the world's best-selling biological drugs, setting up a regulatory knowledge base on approvals and bringing commercial competition to major drugmakers not unlike that seen by small-molecule generics from India decades ago.

Want to take on Gilead in hep C, Merck? Try niche marketing, game theory expert says

In game theory, the so-called Judo strategy involves using the size and strength of opponents against them. And that's exactly what Yale Professor Barry Nalebuff thinks Merck should employ when it rolls out its next-gen hepatitis C regimen, setting up a battle with Gilead and AbbVie.

Inflectra vs. Remicade study could be just what the doctor ordered for biosimilars

A study released today that pitted Hospira's biosimilar Inflectra against its reference drug Remicade in patients with rheumatoid arthritis is good news for Hospira, and by default Pfizer. It found that patients who were switched to the copy did just as well, with no unexpected side effects, as they had on Merck and Johnson & Johnson's Remicade.

Merck aces Phase III with knockoffs of Enbrel and Remicade

Merck's copies of the blockbuster anti-inflammatory treatments Enbrel and Remicade met their goals in Phase III, burnishing the pharma giant's plans to elbow its way into the long queue of companies readying cheaper versions of some of the world's best-selling medicines.

Merck's best hep C strategy is niche marketing, game theory expert figures

The market for next-gen hepatitis C drugs is already dominated by Gilead and AbbVie, who boast exclusive contracts with the country's largest pharmacy benefits managers and health insurers. But Merck & Co. is prepping its own contender, which could launch next year. What should it do to win a piece of the pie?